arrow
A

Arnaud Jannin

CHU de Lille
H指数:18
被引数:1,186

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

P4 - ECE_2057 - Diagnostic jouney and delays in patients with pheochromocytoma and abdominal paraganglioma: from symptom onset to post-surgical outcomes

P4 - ECE_2057 - 嗜铬细胞瘤和腹部分布的副神经节瘤患者的诊断过程与延迟:从症状出现到术后结局

2026-08-100
OAAI
NKX6.1 mRNA copy number is an actionable biomarker associated with islet function and clinical outcomes after islet transplantation

NKX6.1 mRNA拷贝数是与胰岛功能及异体移植后临床结局相关的可操作生物标志物。

2026-03-250
PRE
French expert consensus statement on diagnosis and MANAGEMENT of PRIMARY HYPERPARATHYROIDISM

法国专家共识声明:原发性甲状旁腺功能亢进的诊断与管理

2025-08-300
PRE
ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer

ENDOCAN TUTHYREF网络共识建议:难治性滤泡性甲状腺癌

2025-05-070
PRE
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks

局部晚期或转移性胸腺神经内分泌肿瘤患者的特征,预后和治疗: 法国GTE,ENDOCAN RENATEN和RYTHMIC网络的回顾性研究

2025-05-040
OAAI
Identification of metabolite biomarkers for pancreatic neuroendocrine tumours using a metabolomic approach

利用代谢组学方法鉴定胰腺神经内分泌肿瘤的代谢物生物标志物

2025-04-010
PRE
Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [18F]FDG PET/CT and 131I Posttreatment Scanning

RET融合、放射性碘难治性分化型甲状腺癌的再分化:[18F]FDG PET/CT与131I治疗后扫描之间的转换

2025-01-160
PRE
Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review
2024-01-3011
OA
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network
THYROID
IF6.7
2023-10-018
PRE